Table 1. Stratified analysis on the association between MCM7 expression and overall survival of HCC patients.

Variable	Total number	MCM7high		MCM7low		HR (95% CI)a	P-valuea
		Case number	MST (month)	Case number	MST (month)
Overall	153	74	26.0	79	46.0	1.64 (1.07–2.51)	0.023
Age (years)
⩽55	93	41	26.0	52	38.0	1.44 (0.84–2.48)	0.182
>55	60	33	28.0	27	>63.0	2.00 (0.97–4.13)	0.062
Gender
Male	101	51	22.0	50	>63.0	1.87 (1.07–3.29)	0.029
Female	52	23	29.0	29	38.0	1.47 (0.75–2.86)	0.264
Hepatitis virus infection
Negative	43	21	34.0	22	>63.0	2.40 (0.90–6.42)	0.08
Positive	110	53	20.0	57	38.0	1.53 (0.94–2.46)	0.084
Cirrhosis
Absent	55	25	49.0	30	>62.0	1.48 (0.64–3.43)	0.361
Present	98	49	15.0	49	37.0	1.74 (1.06–2.87)	0.028
Child–Pugh score
A+B	142	69	28.0	73	48.0	1.62 (1.03–2.54)	0.035
C	11	5	17.0	6	29.0	2.93 (0.63–13.71)	0.173
Serum AFP level (ng/ml)
<200	76	35	32.0	41	52.0	2.46 (1.23–4.92)	0.011
⩾200	77	39	15.0	38	25.0	1.22 (0.71–2.11)	0.468
Tumor size (cm)
⩽5	99	45	29.0	54	>63.0	1.98 (1.11–3.54)	0.021
> 5	54	29	18.0	25	26.0	1.08 (0.57–2.04)	0.823
Tumor number
Single	103	45	26.0	58	39.0	1.84 (1.08–3.13)	0.024
Multiple (⩾2)	50	29	31.0	21	41.0	1.25 (0.60–2.58)	0.550
Capsule integrity
Yes	70	35	26.0	35	46.0	1.74 (0.94–3.24)	0.078
No	83	39	27.0	44	39.0	1.51 (0.84–2.73)	0.173
Venous invasion
Negative	111	47	28.0	64	>63.0	1.92 (1.14–3.25)	0.015
Positive	42	27	10.0	15	18.0	0.44 (0.35–1.57)	0.440
Differentiation
Edmonson I–II	82	31	52.0	51	>63.0	1.65 (0.83-3.29)	0.152
Edmonson III–IV	71	43	22.0	28	27.0	1.16 (0.66–2.02)	0.609
TNM stage
I+II	112	48	28.0	64	>63.0	1.77 (1.04–3.00)	0.036
III	41	26	13.0	15	23.0	0.91 (0.43–1.92)	0.808
BCLC stage
A–B	106	46	28.0	60	>63.0	2.03 (1.18–3.47)	0.010
C	47	28	18.0	19	16.0	0.84 (0.42–1.71)	0.632

Abbreviations: BCLC, Barcelona clinic liver cancer; CI, confidence interval; HR, hazard ratio; MST, median survival time

^aHR and P-value were derived from univariate analysis. The significant P-values (<0.05) are in bold